Table 2.
Results of the AZA-001 trial of azacitidine versus conventional care in patients with myelodysplastic syndromes13
| AzacitidineN= [179] | Conventional careN= [179] | P | |
|---|---|---|---|
| Median overall survival (mo) | 24.5 | 15.0 | P ≤ 0.0001 |
| 2-year overall survival (%) | 50.8 | 26.2 | P < 0.0001 |
| Median time to AML (mo) | 17.8 | 11.5 | P ≤ 0.0001 |
| Cytogenetic overall survival (mo) | |||
| −7/del (7q) | 13.1 | 4.6 | P = 0.0017 |
| Response (%) | |||
| CR | 17 [30] | 8 [14] | P = 0.015 |
| PR | 12 [21] | 4 [7] | P = 0.0094 |
| Stable disease | 42 [75] | 36 [65] | P = 0.33 |
Notes: Definitions of hematological response and improvement were based on the International Working Group 2000 criteria for MDS.
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; PR, partial remission.